Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Sunday, June 24, 2018 · 452,935,217 Articles · 3+ Million Readers

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, January 16, 2018 /EINPresswire.com/ -- PetVivo Holdings, Inc. Adds Mr. Thomas Yezzi to Advisory Board.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )


PRESS RELEASE

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Minneapolis, MN Jan. 16, 2018 PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company, is excited with the addition of Mr. Thomas Yezzi to the Advisory Board. Mr. Yezzi has over 20 years’ experience in the food ingredient and biotech industry, and has developed a broad network of venture partners, investors, and research scientists. His entrepreneurial focus has been on start-up and early stage companies. He is currently the President and Founder of Nu-Tek Products, a business incubator for wellness foods and life sciences ventures. He also serves as the President of two portfolio companies, Nu-Tek BioSciences and Nu-Tek Fibers.
Mr. Yezzi was a co-founder of Nu-Tek Salt. He served as President through the start-up and commercialization phases of the Company. His efforts contributed to sizeable funding from large VC’s such as Khosla Ventures.
Mr. Yezzi has also held senior management positions in Operations, Business Development, and Process Development. He was the Vice President of Operations at Protient, Inc., a value-added food ingredient company focusing on the fractionation and purification of milk, whey, and soy proteins. He helped build Protient into a successful food ingredient business using venture capital seed/start-up money. The company was sold in 2005 to one of Europe’s largest food companies. From 1993 to 2000, Mr. Yezzi was Director of Process and Product Development at Northern Food & Dairy, Inc., A SunOpta Company. He managed and generated new business in the nutraceutical, soy, and dairy industries. Tom successfully led many projects from the lab into commercial production. The company focused on custom/toll processing for large food companies such as Novartis, Dupont, Quaker Oats, Taiyo, White Wave, and Westbrae.
Mr. Yezzi holds Bachelor’s and Master’s degrees in Food Science from the University of Minnesota. His focus and research were in the areas of food and industrial microbiology.
“It is not only exciting but comfortably familiar having Mr. Yezzi as part of the team after having worked with him before. His skill sets are exceptional in the areas of manufacturing and scaling up. His background in microbiology and the work I have seen him previously involved with, adds greatly to the team that is setting up our labs and manufacturing capabilities.” Stated Wes Hayne, CEO of PetVivo Holdings, Inc.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 952-405-6216
Direct: (763) 443-7272

Wes Hayne
Petvivo Holdings, Inc.
952-405-6216
email us here

Powered by EIN Presswire